3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Interventions
pembrolizumab
36
Carboplatin
28
Paclitaxel
23
Filgrastim
17
Nivolumab
14
Gemcitabine
14
Cyclophosphamide
14
Ifosfamide
13
Cisplatin
13
Docetaxel
12
Specimen Handling
11
Etoposide
11
olaparib
9
Peripheral Blood Stem Cell Transplantation
9
Magnetic Resonance Spectroscopy
8
fludarabine
6
Temozolomide
6
Ipilimumab
6
Fluorouracil
6
Biopsy
6
Albumin-Bound Paclitaxel
6
rucaparib
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Thiotepa
5
Taxes
5
Standard of Care
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
cabiralizumab
×
Genitourinary
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts